Stephen L. Holcombe serves as President, Chief Executive Officer of the Company. Mr. Holcombe was the President and Chief Financial Officer of TransTech Pharma, LLC and High Point Pharmaceuticals, LLC, our predecessors, from 2014 to March 2015, where he previously served as Senior Vice President and Chief Financial Officer from 2002 to 2014. Mr. Holcombe has over 35 years of experience in financial and managerial roles focusing on the execution of private and public financings, developing corporate alliance and partnership strategies and managing relationships with external constituents. Positions that Mr. Holcombe held prior to joining our predecessors include Executive Vice President and Chief Financial Officer of Vanguard Cellular Systems, Inc., one of the largest independent wireless operators in the United States, Executive Vice President and Chief Financial Officer of BuildNet Inc., an e-commerce software solutions provider, and various positions with KPMG Peat Marwick Mitchell. He holds a bachelor’s degree in Accountancy from Wake Forest University.
As the President und Chief Executive Officer of vTv Therapeutics Inc, the total compensation of Stephen Holcombe at vTv Therapeutics Inc is $832,803. There are no executives at vTv Therapeutics Inc getting paid more.
Stephen Holcombe is 63, he's been the President und Chief Executive Officer of vTv Therapeutics Inc since 2015. There are 4 older and 3 younger executives at vTv Therapeutics Inc. The oldest executive at vTv Therapeutics Inc is Howard Weiner, 75, who is the Independent Director.
Stephen's mailing address filed with the SEC is C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT, NC, 27265.
Over the last 9 years, insiders at vTv Therapeutics Inc have traded over $100,050 worth of vTv Therapeutics Inc stock and bought 38,545,137 units worth $116,272,024 . The most active insiders traders include Ronald O Perelman, Srinivas Akkaraju und Bros. Advisors Lp667, L.P.B.... On average, vTv Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $6,926,668. The most recent stock trade was executed by John A Fry on 28 November 2022, trading 61,000 units of VTVT stock currently worth $50,630.
vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.
vTv Therapeutics Inc executives and other stock owners filed with the SEC include: